On the morning of March 3, ZZU and Shijiazhuang No.4 Pharmaceutical Co., Ltd. held a ceremony of patented technology transfer and research development program signing for “ADN – 9 Innovation Drug for Treating Liver Fibrosis”. President Academician Liu Jiongtian and General Manager Su Xuejun signed the agreement of technical patent transfer on behalf of both sides.

The transferred “AND-9” innovation drug, was jointly developed by ZZU’s School of Life Sciences and School of Pharmacy, who based on natural product of Andrographolide, through systematic molecular optimization and research on structure-activity relationship, obtained a candidate drug molecule that applies to treating chronic hepatitis and restraining the progress of liver cancer, especially effective in resisting liver fibrosis. The total fees of technical patent transfer and research and development amount to 50 million RMB, breaking a new record for ZZU in the field of the commercialization of research fruits.(translator Song Gencheng)